Conagra Just Cut Its Dividend in Half. The 10-K Explains Why.
Listen to this report
Initiating coverage · NYSE: CAG · FY2026 10-K (fiscal year ended May 31, 2026, filed July 15, 2026) · All filing figures verified against the SEC XBRL data in the RoboSystems shared repository (CIK 0000023217); market data as of July 15-16, 2026.
The Hook
By early July 2026, Conagra Brands' dividend yield had climbed to nearly 10 percent - not because the payout grew, but because the stock had lost roughly 45 percent of its value in a year. A near-double-digit yield on a packaged-food blue chip is rarely income; it is the market pricing a cut before the board announces one. On July 15, Conagra confirmed it: the quarterly dividend was cut in half, from $0.35 to $0.175 per share ($0.70 annualized), the first reset of a payout that had held at $1.40 since fiscal 2022.
The cut arrived inside one of the ugliest annual reports in the company's history as a standalone brand portfolio. Conagra wrote off $2.93 billion of goodwill and brand value in fiscal 2026 - equal to roughly a third of its starting shareholders' equity - swinging reported operating margin to negative 14.4 percent and the bottom line to a $4.00-per-share loss, even as adjusted EPS came in at $1.72. And the forward guide got worse, not better: fiscal 2027 adjusted EPS of $1.40 to $1.50, down another 16 percent at the midpoint, on organic sales guided down 1 to 3 percent. New CEO John Brase, roughly six weeks into the job, chose to reset everything at once.
Company Snapshot
Conagra Brands is one of North America's largest branded packaged-food companies - a 100-year-old portfolio spanning Birds Eye, Duncan Hines, Healthy Choice, Marie Callender's, Reddi-wip, Slim Jim, and Angie's BOOMCHICKAPOP, organized into four segments: Grocery & Snacks ($4.61B of FY26 net sales), Refrigerated & Frozen ($4.64B), International ($0.91B), and Foodservice ($1.12B). This coverage is built on the FY2026 10-K - a 53-week year ended May 31, 2026 - plus the Q4 earnings release and call. At about $14 per share, the market values the equity at roughly $6.7 billion, against $7.05 billion of net debt.
The Financial Story
The top line has eroded for three straight years. Per the XBRL filing data, net sales peaked at $12.28 billion in FY2023 and have since fallen to $12.05 billion (FY24), $11.61 billion (FY25), and $11.28 billion (FY26) - a cumulative 8 percent decline, and that is with a 53rd week padding FY26 by $204 million. The organic decline in FY26 was a modest 0.4 percent, but its composition is the story: volume down 1.4 percent, price/mix up only 1.0 percent. Management itself expects organic volumes to decline again in FY27 - which, as one analyst noted on the call, would make six consecutive fiscal years of volume declines. Very few high-fixed-cost consumer businesses absorb that without structural damage.
Margins are compressing faster than sales. Reported gross margin has gone from 27.7 percent in FY24 to 25.9 percent in FY25 to 23.9 percent in FY26 - roughly four points of gross margin gone in two years, as cost inflation (guided at 5 to 6 percent again for FY27, led by beef, oil-linked inputs, and logistics) outruns the company's 4-percent-plus productivity program. Adjusted operating margin fell 274 basis points to 11.3 percent in FY26, and the FY27 guide of 10.0 to 10.5 percent concedes another year of compression - versus roughly 16 percent only a few years ago. Adjusted EBITDA fell 17.3 percent to $1.84 billion. The company's answer is inflation-justified pricing landing mid-Q2 of FY27, concentrated in frozen, with guidance assuming price/mix of roughly plus 3 percent against volumes down mid-single digits - deliberately conservative elasticity assumptions, but a bet nonetheless that shoppers already trading toward value will absorb higher shelf prices.
The write-down is the stock price talking back. The $2.93 billion of impairments - $2.38 billion of goodwill (all in Refrigerated & Frozen) plus $547 million of brand intangibles - was triggered, per the 10-K, by "a sustained decline in market capitalization and stock price." It came in two waves: $771 million of goodwill plus Birds Eye and spreads brand charges in Q2, then another $1.61 billion of goodwill and $350 million of brand charges (Birds Eye, Armour, Bertolli, Angie's BOOMCHICKAPOP, Wish-Bone) in Q4 as the stock kept falling and the discount rate moved up another 200 basis points. There is a circularity here worth naming: the falling stock forced the write-down, and the write-down produced the headline $1.92 billion net loss. The cash economics didn't change - but the filing also discloses that the Refrigerated & Frozen reporting unit now carries zero excess fair value over carrying amount, meaning any further deterioration risks yet another impairment. The unit's accumulated impairment losses now total $3.05 billion.
The dividend cut is really a balance-sheet story. Net debt ended FY26 at $7.05 billion - almost exactly the market value of the entire equity - at 3.83 times adjusted EBITDA. Strikingly, leverage is guided to rise to about 4.0 times in FY27 as EBITDA falls, before the company works toward its 3.0-times target. Free cash flow was $979 million in FY26 (down 25 percent), of which the old dividend consumed $670 million. The halved payout frees roughly $335 million a year - about $1 billion over three years per management - for debt paydown plus reinvestment: a 14 percent increase in advertising (to about 3 percent of sales), and capex stepped up to about $550 million, including roughly $100 million to in-source fried-chicken production. Near-term test: $762.5 million of senior notes come due in October 2026 ($500 million at 5.30 percent and $262.5 million at 7.125 percent), with FY28 and FY29 maturities of $1.03 billion and $1.70 billion behind them. Management says all refinancing options - commercial paper, term loans, public notes - are on the table. One genuine bright spot: free cash flow conversion was 119 percent, the third straight year above 115 percent.
Segment detail shows where the pain is concentrated. Grocery & Snacks remains the profit engine: 19.2 percent adjusted operating margin on $4.61 billion of sales, organic sales roughly flat. Refrigerated & Frozen - the strategic centerpiece, and where management is deliberately investing - earned just 10.5 percent adjusted margin, down 351 basis points, with adjusted operating profit down 25.5 percent; it is also where all $2.38 billion of goodwill impairment landed. International (14.7 percent margin) and Foodservice (10.2 percent) are small stabilizers, with Foodservice the only segment growing reported sales for the full year.
Valuation - What It's Worth as a Normal Business
Where it trades. At roughly $14.09 (July 15 close), Conagra's market cap is about $6.7 billion and enterprise value about $13.8 billion. Trailing P/E is meaningless (reported loss); on the FY27 guide midpoint of $1.45, the forward P/E is about 9.7 times. Price-to-sales is 0.60 times. EV to FY26 adjusted EBITDA is 7.5 times; on our rough FY27 estimate of about $1.67 billion of adjusted EBITDA it is roughly 8.2 times. Trailing FCF yield on the equity is a striking 14.5 percent, and even FY27's guided-down free cash flow (roughly $650 to $700 million on 90-percent-plus conversion) implies a near-10-percent yield. The reset dividend yields about 5 percent at a 48 percent payout of guided EPS - right inside the company's stated 50-to-55-percent long-term target. Analyst consensus sits at Hold with an average target near $14.30 - the street, like the market, is pricing a show-me story. Peers frame the discount: General Mills trades near 12 times forward earnings and 9.7 times EV/EBITDA (and, notably, also posted an impairment-driven trailing loss - this is a sector-wide de-rating, not just a Conagra problem).
Scenario DCF (implied value under stated assumptions - not a price target). We modeled free cash flow to the firm over five years with a terminal value, subtracting $7.05 billion of net debt across roughly 479 million shares. Base case: FCF starts near the FY27 guide (about $660 million), recovers to about $900 million by FY31 as pricing wraps, productivity flows through, and capex normalizes; 7.5 percent discount rate, 1.5 percent terminal growth. That yields an enterprise value near $13.7 billion and an equity value of about $14 per share - almost exactly today's price. Bull case: margins rebuild toward historical levels, FCF reaches $1.1 billion by FY31, 7.25 percent discount rate, 1.75 percent terminal growth - roughly $22 to $24 per share. Bear case: pricing fails, volumes keep falling, FCF stalls around $550 to $620 million and declines thereafter - on a pure DCF the $7 billion debt stack absorbs nearly the entire enterprise value, leaving the equity worth little (a friendlier exit-multiple approach, 7 times depressed EBITDA, still yields only around $8). This asymmetry is the single most important thing to understand about the stock: with net debt equal to the market cap, the equity is a leveraged slice of the enterprise, and it swings violently in both directions.
Peer re-rating cross-check. Apply General Mills-like multiples to Conagra's guided numbers: 11 to 12 times forward EPS of $1.45 implies $16 to $17.40; 8.5 to 9.5 times our FY27 EBITDA estimate implies roughly $15 to $18.50 per share. Blending the approaches, the implied-value range runs from the mid-single digits (bear) through roughly $14 (base) to the low $20s (bull), with the re-rating math clustering at $15 to $18.50. What today's $14 price implies: the market believes the FY27 plan roughly as guided - no re-rating toward peers, but no further unraveling either. To be explicit: these are implied values under stated assumptions, not price targets, and none of this is investment advice.
Risks
The risks are unusually concrete. First, elasticity: the plan raises frozen prices into a value-seeking consumer - the 10-K's risk factors explicitly flag that "growing use of weight loss medication has caused, and may continue to cause, shifts in consumer preferences," alongside private-label and value-channel competition; if volumes fall harder than the assumed mid-single digits, the pricing plan unwinds. Second, the balance sheet: leverage rising to about 4.0 times while $762.5 million of notes mature in October 2026 leaves little room for a guidance miss, and the Refrigerated & Frozen unit's zero-cushion carrying value means any shortfall likely brings another headline impairment. Third, litigation: the 10-K discloses $141 million paid in FY26 to settle Pam cooking-spray product-liability claims (plus $44.3 million due in Q1 FY27 and a contested $22.9 million Esparza judgment), ongoing Beatrice-era environmental liabilities (about a $39 million accrual across roughly 35 Superfund-related sites), and a pending wave of suits alleging harm from "ultra-processed" foods - an emerging, industry-wide legal theory worth watching. Fourth, execution: a brand-new CEO is running a pricing pivot, a SKU rationalization across roughly 5,500 SKUs, an in-sourcing capex program, and a portfolio review simultaneously, with the full strategy not due until an Investor Day in early 2027. Tariffs add a further $40 million headwind, front-loaded into Q1 FY27.
The Bottom Line
Fiscal 2026 was the year Conagra stopped defending the old story. The dividend that was never quite affordable is now covered; the goodwill that reflected a bigger, healthier business is now written down to reality; and guidance now assumes the consumer stays difficult. The equity at $14 is neither obviously cheap nor obviously doomed - it is a leveraged bet on a specific, dated plan: pricing lands mid-Q2 without a volume collapse, gross margin stabilizes, leverage peaks near 4.0 times and turns down, and the October maturities refinance smoothly. Watch those four markers, plus the early-2027 Investor Day where Brase shows his portfolio hand. If the plan holds, the re-rating math points meaningfully higher; if it slips, the debt stack - not the dividend - becomes the story again. Framework, not a recommendation.
Built with RoboSystems - structured SEC filing data for every public company, queryable from the original XBRL. Explore it at robosystems.ai. New customers get 50% off your first month with code ROBO50.